Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31740435 | 0.84 | HPGD (0.50) | KDM4ECYP1A2HTT | |
| SCHEMBL30456080 | 0.81 | ALDH1A1 (0.54) | HTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL25269396 | 0.81 | ALDH1A1 (0.54) | HTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL31705145 | 0.81 | PTK2 (0.63) | KDM4ECYP1A2 | |
| SCHEMBL25719397 | 0.81 | PTK2 (0.63) | KDM4ECYP1A2 | |
| SCHEMBL29880381 | 0.80 | KIT (0.55) | HTT | |
| SCHEMBL29936658 | 0.78 | PTK2 (0.67) | HTR2CKDM4ECYP1A2CYP3A4HTT | |
| SCHEMBL1029331 | 0.78 | PTK2 (0.67) | HTR2CKDM4ECYP1A2CYP3A4HTT | |
| SCHEMBL29813234 | 0.76 | HTR2A (0.46) | HTR2CHTT | |
| Hydrochloric Acid SCHEMBL2797449 | 0.76 | PTK2 (0.65) | HTR2CKDM4ECYP1A2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR2C 2901/4885KDM4E 2590/4885CYP1A2 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.